How to buy IDEXX Laboratories (IDXX) shares in the UK

Learn how to easily invest in IDEXX Laboratories shares.

IDEXX Laboratories Inc (IDXX) is a leading diagnostics and research business based in the US. In the week up to 9 January IDEXX Laboratories shares plunged 16.43% to a closing position of $550.3. However, over the last 12 months, IDEXX Laboratories's share price has risen by 22.45% from $496.44. IDEXX Laboratories is listed on the NASDAQ and employs 9,800 staff. All prices are listed in US Dollars.

How to buy shares in IDEXX Laboratories

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: IDXX in this case.
  5. Research IDEXX Laboratories shares. The platform should provide the latest information available.
  6. Buy your IDEXX Laboratories shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted IDEXX Laboratories's share price?

Since the stock market crash that started in February 2020, IDEXX Laboratories's share price has had significant positive movement.

Its last market close was $511.15, which is 45.59% up on its pre-crash value of $278.11 and 203.08% up on the lowest point reached during the March 2020 crash when the shares fell as low as $168.65.

If you had bought $1,000 worth of IDEXX Laboratories shares at the start of February 2020, those shares would have been worth $664.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,855.47.

IDEXX Laboratories share price (NASDAQ:IDXX)

Use our graph to track the performance of IDXX stocks over time.

IDEXX Laboratories shares at a glance

Information last updated 2021-12-10.
Open$612.52
High$618.15
Low$605.75
Close$607.9
Previous close$607.58
Change$0.32
Change %0.0527%
Volume284,679
Information last updated 2022-01-17.
52-week range$455.23 - $706.95
50-day moving average$612.5108
200-day moving average$615.7999
Wall St. target price$706.17
PE ratio60.7192
Dividend yieldN/A (0%)
Earnings per share (TTM)$8.718
Promoted
eToro Free Stocks

Invest in IDEXX Laboratories shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 5x IDEXX Laboratories shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £11.22
£2,255.28 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £5.61
£2,249.67 total
Capital at risk
Stake logo £0 £50 £11.22
£2,255.28 total
Capital at risk
IG Share Dealing logo £0 £250 £18.64
£2,262.70 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £34.39
£2,278.45 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £41.65
£2,285.71 total
Capital at risk
Fineco logo £0 No minimum £22.44
£2,266.50 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £37.55
£2,281.61 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy IDEXX Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is IDEXX Laboratories under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, IDEXX Laboratories shares trade at around 61x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, IDEXX Laboratories's P/E ratio is best considered in relation to those of others within the diagnostics & research industry or those of similar companies.

PEG ratio

IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.0203. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider IDEXX Laboratories's PEG ratio in relation to those of similar companies.

EBITDA

IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $1 billion (£0.0 million).

The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Financials

Revenue TTM $3.1 billion
Operating margin TTM 29.28%
Gross profit TTM $1.6 billion
Return on assets TTM 25.88%
Return on equity TTM 12.65%
Profit margin 24.14%
Book value $8.892
Market capitalisation $44.9 billion

TTM: trailing 12 months

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.

Total ESG risk score

IDEXX Laboratories's total ESG risk: 29.79

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 29.79 (as at 01/01/2019) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare IDEXX Laboratories's total ESG risk score against those of similar companies.

Environmental score

IDEXX Laboratories's environmental score: 9.93/100

IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

IDEXX Laboratories's social score: 14.44/100

IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

IDEXX Laboratories's governance score: 17.91/100

IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Environmental, social, and governance (ESG) summary

IDEXX Laboratories Inc was last rated for ESG on: 2019-01-01.

Total ESG score 29.79
Total ESG percentile 54.84
Environmental score 9.93
Environmental score percentile 6
Social score 14.44
Social score percentile 6
Governance score 17.91
Governance score percentile 6

IDEXX Laboratories share dividends

We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

You may also wish to consider:

Have IDEXX Laboratories's shares ever split?

IDEXX Laboratories's shares were split on a 2:1 basis on 16 June 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.

Share price volatility

Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as $455.23 up to $706.95. A popular way to gauge a stock's volatility is its "beta".

IDXX.US volatility(beta: 0.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 0.9473. This would suggest that IDEXX Laboratories's shares are less volatile than average (for this exchange).

To put IDEXX Laboratories's beta into context you can compare it against those of similar companies.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site